From January 1, 2007 to December 31, 2011 at FUSCC, only 35.2% (258/732) of HER2-positive primary breast cancer patients received one year of adjuvant trastuzumab18, while 83% of such patients in the United States received this treatment. The gene discussed is ERBB2; the disease is breast carcinoma.